CXCR4 and pulmonary arterial hypertension: Therefore, we verified that a CXCR4 inhibitor, silibinin, can ameliorate PAH, possibly through the suppression of the CXCR4/SDF-1 axis, until the point where PAH becomes a severe and irreversible condition [15].